16:12:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-08-25 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning OBSRV 0.00 NOK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning OBSRV 0.00 NOK
2022-06-03 Kvartalsrapport 2022-Q1
2022-06-03 Årsstämma 2022
2022-03-29 Bokslutskommuniké 2021
2022-02-04 Extra Bolagsstämma 2022
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019


ListaOAX Equities
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo, Norge.
2023-03-03 14:10:39
Oslo, 3 March 2023 - Observe Medical ASA ("the Company" or "Observe Medical")
today provides an update on the initial letters of intent (LOIs) that have been
sent to distributors of the Unometer portfolio.

As previously announced, Observe Medical is in the process of confirming orders
with distributors of Unometer Safeti Plus, AbdoPressure and Sippi. Since the
first LOIs were sent out in the middle of February 2023, the order value of
those that have been signed and returned for the Unometer urine measurement
system amount to approximately EUR 1 million. The company expects further
volumes to be confirmed in the coming weeks.

The company continues to experience strong demand and consumer commitment for
the Unometer product portfolio and will, at the back of the signed LOIs,
initiate contract discussions to secure volume commitments for 2023 and 2024.

"We are excited by the level of commitment displayed by distributors of the
Unometer portfolio. This marks the beginning of our work to secure steady
revenue streams through established sales channels and takes us closer to our
ambition to achieve a revenue run rate of NOK 200-250 million by the end of
2023. Moving forward, we will continue, as we have until now, to build strong
relationships with distributors and work towards becoming a leading urine
measurement provider in Europe," said Rune Nystad, CEO of Observe Medical.

For further information, please contact:

Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com

Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and
sells innovative medtech products for the global market. The Company is
committed to improving patient welfare and patient outcomes, improving clinical
data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales
and commercialisation of its broad portfolio of medical technology products,
mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound
care, in combination with targeted M&A. The Company is headquartered in Oslo,
Norway, with additional offices in Narvik (Norway), Gothenburg (Sweden), Oulu
(Finland), and Seattle (the US). In addition, Observe Medical has a direct
sale organisation in the Nordics and a distributor network internationally.

Further information is available at www.observemedical.com.